Pfizer obesity treatment, a once-promising potential solution for weight management, has faced recent setbacks as the company discontinues its development of danuglipron, an oral drug designed to combat obesity.Announced on Tuesday, this decision follows serious concerns related to a potential drug-induced liver injury experienced by a participant in the clinical trials for obesity.